Is losartan the true panacea for aneurysm disease? PRO
- PMID: 20452541
- DOI: 10.1016/j.ccl.2010.02.005
Is losartan the true panacea for aneurysm disease? PRO
Abstract
Aortic aneurysms remain a common medical condition in the twenty-first century. Although surgical repair remains the standard of care for patients with enlarging and advanced aneurysmal disease, new insights into the pathogenesis of aortic aneurysm have resulted in an interest in targeting these pathways and reducing the rate of aneurysm expansion. The renin-angiotensin system is known to play a role in inflammation and aneurysm formation through nuclear factor-kappaB and expression of matrix degrading enzymes. Recent work also suggests that angiotensin receptor blockade may also disrupt transforming growth factor beta1 signaling, resulting in a reduced rate of aneurysm expansion. These animal data, combined with recent retrospective trials showing markedly reduced rates of aortic root dilation in patients with Marfan syndrome treated with angiotensin receptor blockers, suggest a powerful role for angiotensin receptor blockers in the treatment of aortic aneurysms.
Copyright 2010. Published by Elsevier Inc.
Comment in
-
Is losartan the true panacea for aneurysm disease? CON.Cardiol Clin. 2010 May;28(2):279-85. doi: 10.1016/j.ccl.2010.01.003. Cardiol Clin. 2010. PMID: 20452542 Review.
-
Editorial comment: losartan-based medical therapy for aneurysm disease.Cardiol Clin. 2010 May;28(2):287-8. doi: 10.1016/j.ccl.2010.02.015. Cardiol Clin. 2010. PMID: 20452543 No abstract available.
Similar articles
-
Is losartan the true panacea for aneurysm disease? CON.Cardiol Clin. 2010 May;28(2):279-85. doi: 10.1016/j.ccl.2010.01.003. Cardiol Clin. 2010. PMID: 20452542 Review.
-
The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications.Pharmacol Ther. 2011 Jul;131(1):50-60. doi: 10.1016/j.pharmthera.2011.04.002. Epub 2011 Apr 12. Pharmacol Ther. 2011. PMID: 21504760 Review.
-
Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.Scand J Urol Nephrol. 2005;39(6):511-7. doi: 10.1080/00365590510031264. Scand J Urol Nephrol. 2005. PMID: 16303729 Clinical Trial.
-
Pravastatin reduces Marfan aortic dilation.Circulation. 2011 Sep 13;124(11 Suppl):S168-73. doi: 10.1161/CIRCULATIONAHA.110.012187. Circulation. 2011. PMID: 21911808
-
New insights in the pathogenesis of aortic aneurysms.Verh K Acad Geneeskd Belg. 2008;70(2):69-84. Verh K Acad Geneeskd Belg. 2008. PMID: 18630721 Review.
Cited by
-
Histone Deacetylase Inhibition Attenuates Aortic Remodeling in Rats under Pressure Overload.Biomed Res Int. 2020 Jul 24;2020:4705615. doi: 10.1155/2020/4705615. eCollection 2020. Biomed Res Int. 2020. PMID: 32775424 Free PMC article.
-
Characterization and functional elucidation of CD8+AT2+ lymphocytes in human thoracic aortic aneurysm.Int J Clin Exp Pathol. 2017 Jul 1;10(7):7427-7433. eCollection 2017. Int J Clin Exp Pathol. 2017. PMID: 31966585 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical